Wells Fargo & Company Cardiff Oncology, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 32,064 shares of CRDF stock, worth $129,217. This represents 0.0% of its overall portfolio holdings.

Number of Shares

32,064

Previous 23,213 38.13%

Holding current value

$129,217

Previous $61,000 127.87%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$2.31 - $5.35 $20,445 - $47,352	8,851 Added 38.13%	32,064 $139,000
Q3 2024 Nov 13, 2024	BUY	$2.05 - $2.77 $397 - $537	194 Added 0.84%	23,213 $61,000
Q2 2024 Aug 13, 2024	BUY	$2.22 - $5.89 $33,730 - $89,492	15,194 Added 194.17%	23,019 $51,000
Q1 2024 May 10, 2024	BUY	$1.46 - $5.91 $7 - $29	5 Added 0.06%	7,825 $41,000
Q4 2023 Feb 09, 2024	BUY	$0.96 - $1.55 $16 - $26	17 Added 0.22%	7,820 $11,000
Q3 2023 Nov 13, 2023	BUY	$1.38 - $2.18 $5 - $8	4 Added 0.05%	7,803 $10,000
Q2 2023 Aug 15, 2023	BUY	$1.37 - $1.95 $16 - $23	12 Added 0.15%	7,799 $11,000
Q1 2023 May 12, 2023	BUY	$1.45 - $2.09 $8,850 - $12,757	6,104 Added 362.69%	7,787 $12,000
Q4 2022 Feb 13, 2023	BUY	$1.22 - $1.66 $18 - $24	15 Added 0.9%	1,683 $2,000
Q3 2022 Nov 14, 2022	SELL	$1.54 - $3.21 $33 - $70	-22 Reduced 1.3%	1,668 $2,000
Q2 2022 Aug 12, 2022	SELL	$1.17 - $2.61 $8,915 - $19,888	-7,620 Reduced 81.85%	1,690 $4,000
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $24,980 - $85,832	-11,839 Reduced 55.98%	9,310 $23,000
Q4 2021 Feb 14, 2022	BUY	$5.18 - $7.24 $94,115 - $131,543	18,169 Added 609.7%	21,149 $127,000
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $10,345 - $15,652	2,065 Added 225.68%	2,980 $20,000
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $33,602 - $50,732	-5,053 Reduced 84.67%	915 $6,000
Q1 2021 May 13, 2021	SELL	$9.1 - $19.57 $328,983 - $707,494	-36,152 Reduced 85.83%	5,968 $56,000
Q4 2020 Feb 09, 2021	BUY	$12.02 - $24.71 $500,068 - $1.03 Million	41,603 Added 8047.0%	42,120 $757,000
Q3 2020 Nov 05, 2020	BUY	$4.25 - $14.19 $1,904 - $6,357	448 Added 649.28%	517 $8,000
Q2 2020 Aug 13, 2020	BUY	$0.78 - $5.1 $53 - $351	69 New	69 $0

Others Institutions Holding CRDF

# of Institutions

125

Shares Held

25.3M

Call Options Held

866K

Put Options Held

203K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $175M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Cardiff Oncology, Inc. Transaction History